REGENERON PHARMACEUTICALS, INC. business relationships

“These include a license agreement with Bristol-Myers Squibb, E.” SEC filing

“(a) In collaboration with Bayer outside the United States” SEC filing

“Under the terms of the Roche collaboration, Roche distributed and recorded net product sales of Ronapreve ™ outside the United States, and the parties shared gross profits from sales based on a pre-specified formula.” SEC filing

“We rely on Bayer with respect to the commercialization of EYLEA HD and EYLEA outside the United States.” SEC filing

“For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E.” SEC filing

“Under the terms of the collaboration, Sanofi is generally responsible for funding 80% to 100% of agreed-upon development expenses as incurred.” SEC filing

“For example, Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product.” SEC filing

“In addition, we rely on Sanofi to lead much of the clinical development efforts, assist with or lead efforts to obtain and maintain regulatory approvals, and lead the commercialization efforts for these products and product candidates.” SEC filing

“We and Alnylam Pharmaceuticals, Inc. are parties to a collaboration to discover, develop, and commercialize RNAi the rapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system, in addition to a select number of targets expressed...” SEC filing

“(b) In connection with our license agreement with Kiniksa Pharmaceuticals, Ltd., we are entitled to receive 50% of Kiniksa's profits from sales of ARCALYST” SEC filing

“We and Intellia Therapeutics, Inc. are parties to a license and collaboration agreement to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development, including therapies focused on neurological and muscular diseases.” SEC filing

“In January 2025, RGC entered into an agreement with Truveta Inc. pursuant to which RGC will sequence exomes and conduct genotyping and imputation of up to ten million de-identified consented volunteers using biospecimens provided by Truveta health system members across the United States.” SEC filing

“The jury awarded Regeneron $ 135.6 million in compensatory damages on its antitrust claims (which are subject to trebling under applicable law), or in the alternative, in compensatory damages plus $ 271.2 million in punitive damages on its tortious interference claim, with such damages under either...” SEC filing

“Regeneron alleges that Amgen's sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payers and PBMs have harmed the sales of its product PRALUENT ® and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potent...” SEC filing

“(1) In partnership with Regeneron.” SEC filing

“On December 19, 2025, Alvotech and Teva announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc., concerning the launch of Alvotech's proposed biosimilar to Eylea” SEC filing

“Through the Amended C5 License Agreement, Regeneron is now solely responsible for development, manufacturing and commercialization of cemdisiran as a monotherapy and in combination with anti-C5 antibodies.” SEC filing

“...Zeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences, Ltd., as well as our collaborators Regeneron, Roche, Sanofi and Vir.” SEC filing

“In December 2025, Alvotech and Teva reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States.” SEC filing

“In Japan, in October 2025, Regeneron and Bayer brought a petition for provisional disposition against Alvotech's commercial partner Fuji Pharma based on Japanese patent no.” SEC filing

“(10) In collaboration with Regeneron.” SEC filing

“August 25, 2023, the Company entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc.” SEC filing

“On October 28, 2025, ModeX entered into a license and collaboration agreement (the "Regeneron Collaboration Agreement") with Regeneron Pharmaceuticals Inc. ("Regeneron") to discover and develop multispecific antibodies for several therapeutic indications of mutual interest.” SEC filing

“...d of gross profit share and royalty payments for NGENLA ® and Pfizer's Genotropin, a $ 7.0 million upfront payment from Regeneron, $ 4.3 million in royalty revenue from Eli Lilly following the commercial launch of Mazdutide in China and $ 7.4 million from contract manufacturers' commercial milestone...” SEC filing

“Please see "-License and Collaboration Agreements-Approved Products-Regeneron" for a description of our license agreement with Regeneron.” SEC filing

“Evkeeza is approved in the U.S., where it is marketed by our partner Regeneron Pharmaceuticals, or Regeneron.” SEC filing

“The Evkeeza drug substance is manufactured by Regeneron at their manufacturing facility in Rensselaer, New York and the drug product is manufactured by Baxter Pharmaceutical Solutions, LLC at their manufacturing facility in Bloomington, Indiana.” SEC filing

“Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron.” SEC filing

“In February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebimetinib in combination with Libtayo in a planned clinical trial of patients with unresectable or meta...” SEC filing

“Regeneron not obligated to accept our forecasts or purchase orders in certain circumstances and Regeneron may not have sufficient manufacturing capacity to meet our commercial or clinical demand for ARCALYST (including increased demand arising from our need to replace material lost to manufacturing...” SEC filing

“We also evenly split with Regeneron any proceeds received by us from any licensees, sublicensees and distributors in consideration for the sale, license or other disposition of rights with respect to ARCALYST, including upfront payments, milestone payments and royalties.” SEC filing

“In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug.” SEC filing

“Collaboration expenses consist of Regeneron's share of the profit related to ARCALYST sales under the Regeneron Agreement and the cost of products sold under collaboration agreements.” SEC filing

“The Company entered into supply agreements with Regeneron to provide both clinical supply and commercial product (see Note 13).” SEC filing

“We expect Yoltech Therapeutics, Cornell University, AIRNA, Prime Medicine, CRISPR Therapeutics, and Tessera Therapeutics (a program that is partnered with Regeneron) each to begin early-stage clinical trials in AATD over the next 12-18 months.” SEC filing

“As of December 31, 2025, the Company's accounts receivable and contract liabilities were related to its collaboration with Regeneron.” SEC filing

“Under this agreement, we also may access the Regeneron Genetics Center and proprietary mouse models to be provided by Regeneron for a limited number of our liver programs.” SEC filing

“...for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“We have also entered into a clinical collaboration agreement with Regeneron, which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted thereunder.” SEC filing

“Master Clinical Trial Collaboration and Supply Agreement, dated as of May 29, 2018, by and between Regeneron Pharmaceuticals, Inc. and the Registrant.” SEC filing

“For example, our former collaborator Regeneron terminated our collaboration in August 2021.” SEC filing

“...e revenue during the year ended December 31, 2024 was $0.2 million and consisted of revenue related to our license agreement with Regeneron Pharmaceuticals, Inc., which we recognized following the grant of two six-month extensions of the option term during the year, each for revenue of $0.1 million.” SEC filing

“We depend substantially on our license agreements with Regeneron, CRISPR and City of Hope.” SEC filing

“In addition to developing CARs and TCRs for use in novel immune-cell therapies as part of the collaboration, Regeneron will have the right to use these CARs and TCRs in our other antibody programs outside of the collaboration.” SEC filing

“...are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“| Supply and Non-Exclusive License Agreement between the Company and Regeneron Pharmaceuticals, Inc. dated February 1, 2021. |” SEC filing

“manufactured and commercialized by Regeneron.” SEC filing

“...mmercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme and Roche.” SEC filing

“Under the Collaboration and License Agreement, the Company granted Regeneron an exclusive, worldwide, royalty-bearing license under certain Company intellectual property to develop, manufacture, commercialize and otherwise exploit licensed products ("Licensed Products") for all human and non-human d...” SEC filing

“Most recently, in November 2022 and December 2022, we entered into strategic collaborations with Regeneron and Moderna, respectively.” SEC filing

“...ng domains of VEGFR1 and VEGFR2, initially approved in 2011 and approved at a higher dose in 2023, is commercialized by Regeneron Pharmaceuticals, Inc. under the brand names Eylea® and EyleaHD®; brolucizumab, a single chain antibody fragment approved in 2019 and sold by Novartis AG under the brand n...” SEC filing

“...their anti-PD-1/PD-L1 antibodies, including AstraZeneca, BeiGene/Novartis, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, and there are also many other anti-PD-1 and anti-PD-L1 antibodies in clinical development.” SEC filing

“Under the Regeneron Letter Agreement, we assumed from Astellas an obligation to make mid-single-digit percentage royalty payments to Regeneron upon the commercialization of products developed from materials originally licensed to Astellas.” SEC filing

“The Regeneron Letter Agreement relates to a prior Non-Exclusive License and Material Transfer Agreement (the "Terminated Regeneron License Agreement") that Regeneron and Astellas entered into in March 2007, as amended in July 2010 and subsequently terminated in June 2018, subject to certain survivin...” SEC filing